These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

101 related items for PubMed ID: 23525983

  • 1. Clinical dose findings of sitafloxacin treatment: pharmacokinetic-pharmacodynamic analysis of two clinical trial results for community-acquired respiratory tract infections.
    Kohno S, Niki Y, Kadota J, Yanagihara K, Kaku M, Watanabe A, Aoki N, Hori S, Fujita J, Tanigawara Y.
    J Infect Chemother; 2013 Jun; 19(3):486-94. PubMed ID: 23525983
    [Abstract] [Full Text] [Related]

  • 2. Population pharmacokinetics and pharmacodynamics of sitafloxacin in patients with community-acquired respiratory tract infections.
    Tanigawara Y, Kaku M, Totsuka K, Tsuge H, Saito A.
    J Infect Chemother; 2013 Oct; 19(5):858-66. PubMed ID: 23529500
    [Abstract] [Full Text] [Related]

  • 3. Proposed Pharmacokinetic-Pharmacodynamic Breakpoint of Garenoxacin and Other Quinolones.
    Yamagishi Y, Shibata T, Nakagawa S, Nomura N, Mitsuyama J, Mikamo H.
    Jpn J Infect Dis; 2017 Nov 22; 70(6):616-620. PubMed ID: 28890509
    [Abstract] [Full Text] [Related]

  • 4. Population pharmacokinetics and pharmacodynamics of garenoxacin in patients with community-acquired respiratory tract infections.
    Van Wart S, Phillips L, Ludwig EA, Russo R, Gajjar DA, Bello A, Ambrose PG, Costanzo C, Grasela TH, Echols R, Grasela DM.
    Antimicrob Agents Chemother; 2004 Dec 22; 48(12):4766-77. PubMed ID: 15561855
    [Abstract] [Full Text] [Related]

  • 5. Comparison of gatifloxacin and levofloxacin administered at various dosing regimens to hospitalised patients with community-acquired pneumonia: pharmacodynamic target attainment study using North American surveillance data for Streptococcus pneumoniae.
    Noreddin AM, Hoban DJ, Zhanel GG.
    Int J Antimicrob Agents; 2005 Aug 22; 26(2):120-5. PubMed ID: 16046101
    [Abstract] [Full Text] [Related]

  • 6. Moxifloxacin pharmacokinetic profile and efficacy evaluation in empiric treatment of community-acquired pneumonia.
    Öbrink-Hansen K, Hardlei TF, Brock B, Jensen-Fangel S, Kragh Thomsen M, Petersen E, Kreilgaard M.
    Antimicrob Agents Chemother; 2015 Apr 22; 59(4):2398-404. PubMed ID: 25666151
    [Abstract] [Full Text] [Related]

  • 7. Clinical and bacteriological efficacies of sitafloxacin against community-acquired pneumonia caused by Streptococcus pneumoniae: nested cohort within a multicenter clinical trial.
    Fujita J, Niki Y, Kadota J, Yanagihara K, Kaku M, Watanabe A, Aoki N, Hori S, Tanigawara Y, Cash HL, Kohno S.
    J Infect Chemother; 2013 Jun 22; 19(3):472-9. PubMed ID: 23179958
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Efficacy and safety of moxifloxacin for community-acquired bacterial pneumonia based on pharmacokinetic analysis.
    Yoshida K, Okimoto N, Kishimoto M, Fukano H, Hara H, Yoneyama H, Moriya O, Kawanishi M, Kimura M, Matsushima T, Niki Y.
    J Infect Chemother; 2011 Oct 22; 17(5):678-85. PubMed ID: 21847518
    [Abstract] [Full Text] [Related]

  • 12. A randomized, controlled, multicenter clinical trial to evaluate the efficacy and safety of oral sitafloxacin versus moxifloxacin in adult patients with community-acquired pneumonia.
    Li Y, Zhu D, Peng Y, Tong Z, Ma Z, Xu J, Sun S, Tang H, Xiu Q, Liang Y, Wang X, Lv X, Dai Y, Zhu Y, Qu Y, Xu K, Huang Y, Wu S, Lai G, Li X, Han X, Yang Z, Sheng J, Liu Z, Li H, Chen Y, Zhu H, Zhang Y.
    Curr Med Res Opin; 2021 Apr 22; 37(4):693-701. PubMed ID: 33534617
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. [Efficacy and safety of sitafloxacin for lower respiratory tract infections].
    Mukae H, Yatera K, Nagata S, Yamasaki K, Nishida C, Kawanami T, Ishimoto H, Yoshii C, Inoue N, Noguchi S, Awaya Y, Kawajiri T, Imanaga T, Kido T, Choujin Y, Obata H, Matsushima A, Suzuki Y.
    Jpn J Antibiot; 2011 Oct 22; 64(5):281-91. PubMed ID: 22428212
    [Abstract] [Full Text] [Related]

  • 15. Moxifloxacin in lower respiratory tract infections: in silico simulation of different bacterial resistance and drug exposure scenarios.
    Salem AH, Noreddin AM.
    J Chemother; 2014 Apr 22; 26(2):80-5. PubMed ID: 24090676
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Comparative pharmacodynamics of garenoxacin, gemifloxacin, and moxifloxacin in community-acquired pneumonia caused by Streptococcus pneumoniae: a Monte Carlo simulation analysis.
    Noreddin AM, Reese AA, Ostroski M, Hoban DJ, Zhanel GG.
    Clin Ther; 2007 Dec 22; 29(12):2685-9. PubMed ID: 18201584
    [Abstract] [Full Text] [Related]

  • 18. Optimal antibiotic dosing. The pharmacokinetic-pharmacodynamic interface.
    Reed MD.
    Postgrad Med; 2000 Dec 22; 108(7 Suppl Contemporaty):17-24. PubMed ID: 19667545
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Pharmacodynamic target attainment analysis against Streptococcus pneumoniae using levofloxacin 500 mg, 750 mg and 1000 mg once daily in plasma (P) and epithelial lining fluid (ELF) of hospitalized patients with community acquired pneumonia (CAP).
    Noreddin AM, Marras TK, Sanders K, Chan CK, Hoban DJ, Zhanel GG.
    Int J Antimicrob Agents; 2004 Nov 22; 24(5):479-84. PubMed ID: 15519481
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.